Clinical data of the patients studied
Patient . | R/NR . | Sex . | Age . | Stage . | Isotype/light chain . | CD38 (%) . | Sample . |
---|---|---|---|---|---|---|---|
1 | R | F | 80 | 0 | IgM-D/λ | 92 | PB |
2 | R | M | 65 | 0 | IgG/κ | 1 | PB |
3 | R | F | 76 | 0 | IgG/λ | 6 | PB |
4 | R | M | 81 | IV | IgM-D/λ | 33 | PB |
5 | R | F | 53 | III-IV | IgM-D/κ | 54 | BM |
6 | R | F | 64 | 0 | IgM-D/λ | 6 | PB |
7 | R | M | 67 | II | IgM/κ | 82 | BM |
8 | R | F | 79 | III | IgM-D/λ | 54 | PB |
9* | R | M | 84 | II | IgM-D/λ | 3 | PB |
10* | R | F | 73 | II | IgM-D/λ | 97 | PB |
11 | R | M | 73 | II | IgM-D/κ | 39 | PB |
12 | R | M | 67 | 0 | IgM-D/κ | 85 | PB |
13 | R | F | 77 | II | IgM-D/κ | 2 | PB |
14 | R | M | 68 | II | IgM-D/κ | 25 | PB |
15 | R | F | 75 | 0 | IgM-D/κ | 66 | PB |
16 | NR | M | 72 | 0 | IgM-D/λ | 30 | PB |
17 | NR | M | 52 | IV | IgM-D/κ | 1 | PB |
18 | NR | F | 67 | IV | IgG/κ | 6 | PB |
19 | NR | M | 67 | 0 | IgM-D/κ | 21 | PB |
20 | NR | F | 72 | IV | IgM-D/κ | 94 | PB |
21 | NR | M | 84 | II | IgM-D/κ | 4 | PB |
22 | NR | F | 68 | 0 | IgM-D/κ | 13 | PB |
23 | ND | M | 73 | 0 | IgM/λ | 4 | PB |
24 | ND | F | 61 | 0 | IgM-D/λ | 18 | PB |
25 | ND | F | 64 | 0 | IgM/κ | 16 | BM |
26 | ND | F | 68 | 0 | IgM-D/κ | 16 | PB |
27 | ND | M | 87 | III | IgM-D/κ | 21 | PB |
28 | ND | M | 70 | II | IgM-D/κ | 14 | PB |
29 | ND | M | 71 | II | IgM-D/κ | 8 | PB |
30 | ND | M | 69 | II | IgM-D/λ | 10 | PB |
Patient . | R/NR . | Sex . | Age . | Stage . | Isotype/light chain . | CD38 (%) . | Sample . |
---|---|---|---|---|---|---|---|
1 | R | F | 80 | 0 | IgM-D/λ | 92 | PB |
2 | R | M | 65 | 0 | IgG/κ | 1 | PB |
3 | R | F | 76 | 0 | IgG/λ | 6 | PB |
4 | R | M | 81 | IV | IgM-D/λ | 33 | PB |
5 | R | F | 53 | III-IV | IgM-D/κ | 54 | BM |
6 | R | F | 64 | 0 | IgM-D/λ | 6 | PB |
7 | R | M | 67 | II | IgM/κ | 82 | BM |
8 | R | F | 79 | III | IgM-D/λ | 54 | PB |
9* | R | M | 84 | II | IgM-D/λ | 3 | PB |
10* | R | F | 73 | II | IgM-D/λ | 97 | PB |
11 | R | M | 73 | II | IgM-D/κ | 39 | PB |
12 | R | M | 67 | 0 | IgM-D/κ | 85 | PB |
13 | R | F | 77 | II | IgM-D/κ | 2 | PB |
14 | R | M | 68 | II | IgM-D/κ | 25 | PB |
15 | R | F | 75 | 0 | IgM-D/κ | 66 | PB |
16 | NR | M | 72 | 0 | IgM-D/λ | 30 | PB |
17 | NR | M | 52 | IV | IgM-D/κ | 1 | PB |
18 | NR | F | 67 | IV | IgG/κ | 6 | PB |
19 | NR | M | 67 | 0 | IgM-D/κ | 21 | PB |
20 | NR | F | 72 | IV | IgM-D/κ | 94 | PB |
21 | NR | M | 84 | II | IgM-D/κ | 4 | PB |
22 | NR | F | 68 | 0 | IgM-D/κ | 13 | PB |
23 | ND | M | 73 | 0 | IgM/λ | 4 | PB |
24 | ND | F | 61 | 0 | IgM-D/λ | 18 | PB |
25 | ND | F | 64 | 0 | IgM/κ | 16 | BM |
26 | ND | F | 68 | 0 | IgM-D/κ | 16 | PB |
27 | ND | M | 87 | III | IgM-D/κ | 21 | PB |
28 | ND | M | 70 | II | IgM-D/κ | 14 | PB |
29 | ND | M | 71 | II | IgM-D/κ | 8 | PB |
30 | ND | M | 69 | II | IgM-D/λ | 10 | PB |
B-PLL
R, CD40L-responder; NR, CD40L-nonresponder; ND, not done.